Acral myxoinflammatory fibroblastic sarcoma: case series and immunohistochemical analysis
- 25 September 2007
- journal article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 35 (2), 192-196
- https://doi.org/10.1111/j.1600-0560.2007.00791.x
Abstract
Background: Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low‐grade neoplasm most often occurring on the extremities of adults. It consists of mixed inflammatory infiltrates with nodules of epithelioid, spindled and bizarre‐appearing cells within a fibrosclerotic‐to‐myxoid stroma. AMFS frequently recurs, but only rarely metastasizes. Materials and methods: A retrospective analysis of all cases of AMFS seen in the past 4 years from the Stanford University Laboratory of Surgical Pathology and collaborating institutions was performed. We sought to better characterize the clinicopathologic characteristics of this rare tumor. Immunohistochemical stains, including CD34, epithelial membrane antigen (EMA), epidermal growth factor receptor (EGFR), CD117, CD163, Ki67 and p53, were also performed. Results: Eighteen cases were analyzed, and clinical information was available on 13 of them. The mean age at diagnosis was 48 years old, 10/13 (77%) occurred on the distal extremities and diameter of the lesions ranged from 1.0 to 10.0 cm. Treatment included wide local or radical excision and local recurrences were not reported. Many of the lesions were multinodular. Histologic characteristics included the presence of fibrosclerotic and myxoid stroma, sheets of spindled to round epithelioid cells, Reed‐Sternberg or virocyte‐like cells, lipoblast‐like cells and rare mitotic figures. In most cases, CD34, EGFR and CD163 were diffusely positive. EMA and CD117 were weakly positive in some cases. Ki67 labeled < 10% of cells, and staining with P53 was variable. Conclusions: Because AMFS may be mistaken for lymphoma, infection or tumors with higher metastatic potential, correct diagnosis is important to avoid unnecessary procedures and allow for proper clinical management. EGFR positivity suggests possible therapeutic use in aggressive cases.Keywords
This publication has 11 references indexed in Scilit:
- Case Reports: Acral Myxoinflammatory Fibroblastic SarcomaClinical Orthopaedics and Related Research, 2006
- Myxoinflammatory fibroblastic sarcoma of the neckJournal of Cutaneous Pathology, 2005
- Acral myxoinflammatory fibroblastic sarcoma in FNAB samples: can we distinguish it from other myxoid lesions?Cytopathology, 2003
- Acral myxoinflammatory fibroblastic sarcoma: a report of five cases and review of the literatureVirchows Archiv A Pathological Anatomy and Histopathology, 2003
- Myxoinflammatory fibroblastic sarcoma: A tumor not restricted to acral sitesAnnals of Diagnostic Pathology, 2002
- Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft partsPathology International, 2002
- Inflammatory Myxohyaline Tumor with Massive EmperipolesisPathology - Research and Practice, 2002
- Akrales myxoinflammatorisches fibroblastisches SarkomDer Pathologe, 2001
- Inflammatory Myxoid Tumor of the Soft Parts with Bizarre Giant CellsPathology - Research and Practice, 1998
- Acral Myxoinflammatory Fibroblastic SarcomaThe American Journal of Surgical Pathology, 1998